Fresh Tracks Therapeutics Inc.
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.59
- Today's High:
- $0.628
- Open Price:
- $0.59
- 52W Low:
- $0.45
- 52W High:
- $2.64
- Prev. Close:
- $0.59
- Volume:
- 30969
Company Statistics
- Market Cap.:
- $3.67 million
- Book Value:
- 1.353
- Revenue TTM:
- $2.60 million
- Operating Margin TTM:
- -668.75%
- Gross Profit TTM:
- $-27827000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -76.61%
- Return on Equity TTM:
- -144.78%
Company Profile
Fresh Tracks Therapeutics Inc. had its IPO on 2022-09-08 under the ticker symbol FRTX.
The company operates in the Healthcare sector and Biotechnology industry. Fresh Tracks Therapeutics Inc. has a staff strength of 13 employees.
Stock update
Shares of Fresh Tracks Therapeutics Inc. opened at $0.59 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.59 - $0.63, and closed at $0.6.
This is a +1.71% increase from the previous day's closing price.
A total volume of 30,969 shares were traded at the close of the day’s session.
In the last one week, shares of Fresh Tracks Therapeutics Inc. have slipped by -3.21%.
Fresh Tracks Therapeutics Inc.'s Key Ratios
Fresh Tracks Therapeutics Inc. has a market cap of $3.67 million, indicating a price to book ratio of 0.392 and a price to sales ratio of 0.8623.
In the last 12-months Fresh Tracks Therapeutics Inc.’s revenue was $2.60 million with a gross profit of $-27827000 and an EBITDA of $-17337000. The EBITDA ratio measures Fresh Tracks Therapeutics Inc.'s overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Fresh Tracks Therapeutics Inc.’s operating margin was -668.75% while its return on assets stood at -76.61% with a return of equity of -144.78%.
In Q2, Fresh Tracks Therapeutics Inc.’s quarterly earnings growth was a positive 0% while revenue growth was a negative 98.8%.
Fresh Tracks Therapeutics Inc.’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-4.78 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Fresh Tracks Therapeutics Inc.’s profitability.
Fresh Tracks Therapeutics Inc. stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.3023. Its price to sales ratio in the trailing 12-months stood at 0.8623.
Fresh Tracks Therapeutics Inc. stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $9.84 million
- Total Liabilities
- $1.85 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Fresh Tracks Therapeutics Inc. ended 2025 with $9.84 million in total assets and $0 in total liabilities. Its intangible assets were valued at $9.84 million while shareholder equity stood at $7.99 million.
Fresh Tracks Therapeutics Inc. ended 2025 with $0 in deferred long-term liabilities, $1.85 million in other current liabilities, 59000.00 in common stock, $-173029000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $8.95 million and cash and short-term investments were $8.95 million. The company’s total short-term debt was $19,000 while long-term debt stood at $0.
Fresh Tracks Therapeutics Inc.’s total current assets stands at $9.71 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $245000.00 compared to accounts payable of $256000.00 and inventory worth $443000.00.
In 2025, Fresh Tracks Therapeutics Inc.'s operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Fresh Tracks Therapeutics Inc. paid $0 in dividends in 2025.
Other key metrics
- Current Trading Price
- $0.6
- 52-Week High
- $2.64
- 52-Week Low
- $0.45
- Analyst Target Price
- $4.5
Fresh Tracks Therapeutics Inc. stock is currently trading at $0.6 per share. It touched a 52-week high of $2.64 and a 52-week low of $2.64. Analysts tracking the stock have a 12-month average target price of $4.5.
Its 50-day moving average was $0.68 and 200-day moving average was $1.08 The short ratio stood at 0.04 indicating a short percent outstanding of 0%.
Around 55.9% of the company’s stock are held by insiders while 358% are held by institutions.
Frequently Asked Questions About Fresh Tracks Therapeutics Inc.
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops FRTX-02 (BBI-02), an oral DYRK1A inhibitor that is completed Phase 1 clinical trials for the treatment of autoimmune and inflammatory diseases; FRTX-10 (BBI-10), a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases; and FRTX-03, a topical DYRK1A inhibitor for the treatment of mild-to-moderate skin conditions, as well as next-generation kinase inhibitors. Fresh Tracks Therapeutics, Inc. has license and collaboration agreements with Carna Biosciences, Inc., and Voronoi Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.